Physician profile
Ned Stein
NPI 1326082843
$2,566.73
in general payments reported to CMS, 2019-2025
27 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $262 · 2021: $406 · 2022: $633 · 2023: $263 · 2024: $365 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $518.18 | 2019-2024 | |
| Boston Scientific Corporation | $319.43 | 2021-2025 | Rezum Generator, Ams 700, Ams 700 Cxr Rte Kit |
| Antares Pharma, INC. | $286.01 | 2022-2025 | Xyosted |
| Endo Pharmaceuticals INC. | $272.48 | 2019-2023 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $225.90 | 2022-2025 | |
| Coloplast Corp | $108.87 | 2019-2025 | |
| Myovant Sciences INC. | $103.04 | 2021-2022 | |
| Astellas Pharma US INC | $91.96 | 2021-2022 | |
| Hollister Incorporated | $69.04 | 2021-2022 | |
| Teleflex LLC | $57.81 | 2021 | |
| Urovant Sciences INC | $56.22 | 2021-2022 | |
| Urogen Pharma, INC. | $44.46 | 2024 | |
| Endo USA, INC. | $43.60 | 2025 | Aveed, Xiaflex |
| Olympus America INC. | $40.17 | 2020-2023 | Itind System |
| Myriad Genetic Laboratories, INC. | $39.43 | 2021-2023 | Prolaris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $32.20 | 2022 | |
| Ferring Pharmaceuticals INC. | $31.01 | 2019 | |
| Telix Pharmaceuticals | $29.99 | 2024 | Illuccix |
| Convatec INC. | $27.66 | 2019 | |
| Merck Sharp & Dohme LLC | $24.93 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.82 | 2019 | |
| Halozyme INC | $22.64 | 2023 | |
| Ambu INC. | $22.25 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.72 | 2025 | Azmiro |
| 180 Medical, INC. | $20.01 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $19.91 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.